Pubdate: Tue, May 04 1999 Source: Oregonian, The (OR) Copyright: 1999 The Oregonian Contact: 1320 SW Broadway, Portland, OR 97201 Fax: 503-294-4193 Website: http://www.oregonlive.com/ Forum: http://forums.oregonlive.com/ Authors: John A. Benson Jr. and Stanley J. Watson Jr. Note: John A. Benson is dean and professor of medicine emeritus, Oregon Health Sciences University School of Medicine, Portland. Stanley J. Watson Jr. is co-director and research scientist at the Mental Health Research Institute, University of Michigan, Ann Arbor. They were co-principal investigators of the institute's study on the medical use of marijuana. THE POT ISSUE: SEPARATING SMOKE FROM SCIENCE * Marijuana Indeed Shows Medical Potential, But The Delivery System Shouldn't Involve Smoking When a study on the medical use of marijuana was issued recently, advocates for legalizing the drug cheered the report's conclusions that marijuana's compounds do have some potential as medicine. Their opponents, however, cited the report's caveat that the harmful effects of smoking far outweigh marijuana's potential benefits for most patients. Both sides are right. And this is not scientific hair-splitting. To date, it has been nearly impossible to separate scientific evidence about marijuana's potential from larger societal concerns about its use. But doing so may be the key to advancing the rancorous debate over this issue since medical marijuana began to appear on state ballot initiatives in the mid-1990s. Some may be surprised to learn that in the scientific realm, we found remarkable consensus that marijuana's components have potential to relieve symptoms such as pain, nausea and vomiting, as well as the poor appetite associated with wasting in cancer or AIDS. For most symptoms, there are more effective drugs already on the market, but physicians encounter patients who do not respond well to standard medications, or who need additional therapies. These patients could benefit from new drugs based on cannabinoids, the active components in marijuana. Marijuana's future as medicine rests in developing new ways of delivering these cannabinoids -- including the most common one, THC. Marinol, a THC capsule, is approved by the Food and Drug Administration for treatment of nausea and vomiting associated with chemotherapy, as well as poor appetite and weight loss associated with AIDS. However, some who have used Marinol complain that it takes effect slowly, and its results are variable. Sufferers, obviously, need fast-acting medication. For that reason, we recommend that clinical trials move forward, with the goal of developing a rapid-onset, non-smoked delivery system, such as an inhaler. This would deliver precise doses without the health problems associated with smoking. But an inhaler could take years to produce. What do we do now? In deciding whether marijuana should be smoked as medicine, society must weigh the reality of this crude drug-delivery system against the benefits it might bestow. Chronic smoking of marijuana increases a person's chances of developing cancer, lung damage and problems with pregnancies, including low birth weight. It simply is not an acceptable long-term option. Smoking should be allowed only for short-term use by patients with debilitating symptoms, or who are terminally ill and do not respond well to approved medications. Even in these cases, marijuana use should be carefully controlled. Patients who are prescribed marijuana should be enrolled in short-term clinical trials involving only those most likely to benefit. These clinical trials of smoked marijuana should not be designed to develop it as a licensed drug, but to make way for developing new, safe delivery systems of cannabinoids. There is no evidence that using marijuana in controlled settings -- or cannabinoids in the form of drugs such as Marinol - -- will lead to increased illicit drug use in society. Our review of the science behind marijuana and cannabinoids convinces us that the debate so far has been miscast. Rather than focusing on drug-control policy, the debate should really be about the promise of future drug development. Mining the pharmaceutical potential of cannabinoids requires the same kind of development that brought us any number of pain-killing drugs prescribed by physicians today. With public investments in research, or enough incentives to convince private companies to develop these drugs, the perceived need to smoke marijuana to alleviate symptoms could vanish. - --- MAP posted-by: Jo-D